1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

医学 彭布罗利珠单抗 肿瘤科 肺癌 内科学 癌症 免疫疗法
作者
A. Calles Blanco,A.F. Navarro Mendivil,B. Doger de Spéville,E. Colomé,María José de Miguel Luken,Rosa Álvarez,Víctor Moreno,Jorge Ramón,M. Arregui Valles,E. Corral de la Fuente,David Hortigüela Alcalá,Marcelo Sanmartín Fernández,J Morató,Emiliano Calvo,Rosario Sánchez,Maria Jové,Enriqueta Felip
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S1060-S1061 被引量:1
标识
DOI:10.1016/j.annonc.2023.09.1220
摘要

Previously, we established the recommended phase 2 dose (RP2D) of LUR + PBL in the phase 1 stage of this study (J Clin Oncol. 2022;40(suppl 16):8581). Here we present the results on the efficacy and safety of the RP2D. LUPER (NCT04358237) is a prospective, open-label, uncontrolled, multicenter, phase 1/2 study of LUR in combination with PBL in patients (pts) with relapsed SCLC. Eligible pts were ≥18 years old, with histologically confirmed SCLC, progression after 1L platinum-based chemotherapy, no prior exposure to immunotherapy, ECOG PS of 0-1, and measurable disease as per RECIST 1.1. Pts with treated, asymptomatic, stable brain metastases (BM) were also included. Treatment consisted of LUR dosed at 3.2 mg/m2 IV Q3W in combination with PBL 200 mg IV Q3W until disease progression (PD), unacceptable toxicity, or consent withdrawal. The primary endpoint was confirmed overall response rate (ORR) according to RECIST 1.1. Secondary endpoints included investigator-assessed Duration of Response (DoR), Progression-Free Survival (PFS), Overall Survival (OS), and safety as per CTCAE 5.0. A total of 28 pts were included in the study. Median age was 65 years (range 41-78), 46.4% were female, 64.3% had ECOG PS of 1, 51.9% had platinum-free interval < 90 days, 39.3% had LDH > upper normal limit, and 21.4% had BM. At data cutoff (March 31, 2023),11 (39.3%) pts were still on treatment. The median follow-up was 5.7 months (range: 1.0-25.2). Preliminary ORR was 46.4% (95% CI: 29.5–64.2; p<0.001): 2 confirmed CR, 11 PR (9 confirmed) and 4 SD ≥12 weeks. Median DoR was 11.4 months (range: 0-21.2 months), and 2 (7.1%) pts had durable responses > 12 months. Median PFS was 5.3 months (95% CI: 2.7-12.0). Median OS was 11.1 months (95% CI: 6.9-NR). PBL and LUR discontinuation occurred in 3 (10.7%) and 0 pts due to immune-related AE, respectively. The most common grade 3 and 4 treatment-emergent AEs (>20%) were fatigue, neutropenia, nausea and anemia. The LUPER study met its primary endpoint. The combination of LUR + PBL is effective in second-line treatment of SCLC with a manageable safety profile. Further research is warranted to confirm the potential of this combination in SCLC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小太阳红红火火完成签到,获得积分10
刚刚
1秒前
orixero应助Steven采纳,获得10
1秒前
yyyjjj完成签到,获得积分20
2秒前
2秒前
2秒前
考拉完成签到,获得积分10
2秒前
yull发布了新的文献求助10
3秒前
罗某人完成签到,获得积分10
3秒前
4秒前
4秒前
聪明凌柏完成签到 ,获得积分10
4秒前
机智猴完成签到,获得积分10
4秒前
4秒前
ananas发布了新的文献求助10
5秒前
SC武完成签到,获得积分10
5秒前
完美的友蕊应助ererrrr采纳,获得10
5秒前
领导范儿应助考拉采纳,获得10
6秒前
6秒前
糟糕的半鬼完成签到,获得积分20
6秒前
7秒前
虎虎生威完成签到,获得积分10
8秒前
yyyjjj发布了新的文献求助10
8秒前
8秒前
zzzkyt发布了新的文献求助10
8秒前
9秒前
充电宝应助Lin采纳,获得10
9秒前
TANG完成签到,获得积分20
9秒前
去去发布了新的文献求助10
10秒前
SYLH应助pppy采纳,获得10
10秒前
fff123完成签到,获得积分10
11秒前
动听又亦发布了新的文献求助10
12秒前
胡国武发布了新的文献求助10
12秒前
bug完成签到,获得积分10
12秒前
美女完成签到 ,获得积分10
12秒前
12秒前
科目三应助辛慧采纳,获得10
13秒前
包容的世倌完成签到 ,获得积分10
15秒前
研友_VZG7GZ应助shinn采纳,获得10
15秒前
mzf发布了新的文献求助10
15秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969458
求助须知:如何正确求助?哪些是违规求助? 3514286
关于积分的说明 11173363
捐赠科研通 3249652
什么是DOI,文献DOI怎么找? 1794948
邀请新用户注册赠送积分活动 875501
科研通“疑难数据库(出版商)”最低求助积分说明 804836